Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
SunovionPharmaceuticals   By Engel Burns
Sunovion PharmaceuticalsSunovion Pharmaceuticals, born from the merging ofDainippon Sumitomo Pharma America, Incorporated(...
Sunovion PharmaceuticalsSunovion remains committed to developing newproducts, and current research includes treatments for...
Sunovion PharmaceuticalsEngel Burns is Sunovion Pharmaceuticals’Federal Account Director of GovernmentAffairs. He was rece...
Upcoming SlideShare
Loading in …5
×

Sunovion pharmaceuticals by engel burns

Sunovion Pharmaceuticals, born from the merging of Dainippon Sumitomo Pharma America, Incorporated (DSPA), and Sepracor, Incorporated, develops treatments for patients suffering from respiratory issues and central nervous system disorders. It is constantly developing new approaches, such as the drug LUNESTA (eszopiclone), which promotes healthy sleeping patterns, and Latuda (lurasidone HCI) for patients with symptoms of schizophrenia. The company’s devotion to nervous system issues is timely. For instance, the World Health Organization ranks schizophrenia as the sixth largest cause of disabilities globally.

  • Be the first to comment

  • Be the first to like this

Sunovion pharmaceuticals by engel burns

  1. 1. SunovionPharmaceuticals By Engel Burns
  2. 2. Sunovion PharmaceuticalsSunovion Pharmaceuticals, born from the merging ofDainippon Sumitomo Pharma America, Incorporated(DSPA), and Sepracor, Incorporated, developstreatments for patients suffering from respiratoryissues and central nervous system disorders. It isconstantly developing new approaches, such as thedrug LUNESTA (eszopiclone), which promoteshealthy sleeping patterns, and Latuda (lurasidoneHCI) for patients with symptoms of schizophrenia.The company’s devotion to nervous system issues istimely. For instance, the World Health Organizationranks schizophrenia as the sixth largest cause ofdisabilities globally.
  3. 3. Sunovion PharmaceuticalsSunovion remains committed to developing newproducts, and current research includes treatments forbipolar disorder, overactive bladder, neuropathicpain, major depressive disorder, diabetes, andAlzheimer’s disease. Research findings are frequentlypublished in peer-reviewed journals, including theJournal of Allergy and Clinical Immunology.Material is also regularly presented at meetings oforganizations such as the National MedicalAssociation and the American Thoracic Society.
  4. 4. Sunovion PharmaceuticalsEngel Burns is Sunovion Pharmaceuticals’Federal Account Director of GovernmentAffairs. He was recently profiled in EbonyMagazine for his achievements in thisposition.

×